Insider · CIK 0002031695
Kevin McCulloch
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Jun 16, 2025, latest Oct 2, 2026.
In brief
Kevin McCulloch files SEC Form 4 as officer at XERS (Xeris Biopharma Holdings, Inc.). Since Jun 16, 2025, Kevin McCulloch has reported 1 open-market buy worth $109k and 6 open-market sells worth $1.5M, the latest filed on Oct 2, 2026.
A track record needs three past buys with six months of prices behind them; Kevin McCulloch has 1, so none is measured yet.
The newest scored trade: sold $141k of XERS on Oct 1, 2026, filed Oct 2, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $1.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Xeris Biopharma Holdings, Inc. | $141k 15,000 shares | -1% | +75% from low-7% from high | |
| 23Weak | Xeris Biopharma Holdings, Inc. | $250k 25,000 shares | -2% | +86% from low-1% from high | |
| 21Weak | Xeris Biopharma Holdings, Inc. | $127k 15,000 shares | -1% | - | |
| 20Weak | Xeris Biopharma Holdings, Inc. | $120k 15,000 shares | -1% | +54% from low-18% from high | |
| 31Weak | Xeris Biopharma Holdings, Inc. | $723k 90,000 shares | -5% | +72% from low-19% from high | |
| 20Weak | Xeris Biopharma Holdings, Inc. | $120k 15,000 shares | -1% | +154% from low-18% from high | |
| 29Weak | XERSbuy Xeris Biopharma Holdings, Inc. | $109k 25,000 shares | +1% | +58% from low-26% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 28, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 70,000 0.04% of outstanding | $637k | Sep 28, 2026 | $970k |
| Jul 1, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 120,000 0.07% of outstanding | $950k | Jul 1, 2026 | none |
| Jan 8, 2026 | XERS XERIS BIOPHARMA HOLDINGS INC | 60,000 0.04% of outstanding | $433k | Jan 8, 2026 | none |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $9.41 | $141k | 1,599,208 | 12 d ago |
| Sep 28, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $10.00 | $250k | 1,614,208 | 15 d ago |
| Sep 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.49 | $127k | 1,639,208 | 43 d ago |
| Aug 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -21,918 | $8.08 | $177k | 1,654,208 | Aug 21, 2026 |
| Aug 3, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.02 | $120k | 1,676,126 | Aug 4, 2026 |
| Jul 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -90,000 | $8.03 | $723k | 1,691,126 | Jul 2, 2026 |
| Mar 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +48,894 | $4.09 | $200k | 1,777,721 | Mar 16, 2026 |
| Mar 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Common Stock | +4 | $3.94 | $16 | 1,777,725 | Mar 16, 2026 |
| Mar 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -48,894 | $4.09 | $200k | 43,773 | Mar 16, 2026 |
| Mar 12, 2026 | XERS Xeris Biopharma Holdings, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -4 | $3.94 | $16 | 79,996 | Mar 16, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +168,463 | $0.00 | $0 | 1,853,889 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -68,454 | $7.36 | $504k | 1,785,435 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -30,289 | $7.36 | $223k | 1,755,146 | Feb 2, 2026 |
| Jan 31, 2026 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -27,319 | $7.36 | $201k | 1,727,827 | Feb 2, 2026 |
| Jan 30, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +225,225 | $0.00 | $0 | 225,225 | Feb 2, 2026 |
| Jan 8, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $8.00 | $120k | 1,685,426 | Jan 9, 2026 |
| Oct 2, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -733 | $8.31 | $6,091 | 1,700,426 | Oct 3, 2025 |
| Sep 11, 2025 | XERS Xeris Biopharma Holdings, Inc. | JOther Common Stockindirect: By Charles R. McCulloch Trust dated 1990 | -2,000 | $0.00 | $0 | 0 | Sep 15, 2025 |
| Aug 1, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -14,651 | $5.38 | $79k | 1,701,159 | Aug 4, 2025 |
| Jun 13, 2025 | XERS Xeris Biopharma Holdings, Inc. | POpen-market purchase Common Stock | +25,000 | $4.38 | $109k | 1,708,585 | Jun 16, 2025 |
| Apr 2, 2025 | XERS Xeris Biopharma Holdings, Inc. | FTax withholding Common Stock | -733 | $5.15 | $3,775 | 1,683,585 | Apr 3, 2025 |
Questions about Kevin McCulloch
Answered from the filings on this page, as of the latest one.
Is Kevin McCulloch buying or selling?
In the last 12 months Kevin McCulloch reported 0 open-market buys worth $0 and 6 open-market sells worth $1.5M on SEC Form 4; the latest was sold $141k of XERS on Oct 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Kevin McCulloch's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin McCulloch has 1.
Where does Kevin McCulloch file Form 4?
Kevin McCulloch has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.